Epidermal growth factor receptor (EGFR) is a transmembrane receptor with a cytoplasmic
tyrosine kinase (TK) domain present on many solid tumors including non-small cell lung …

Erlotinib is an orally small molecule inhibiting the tyrosine kinase activity of the epidermal
growth factor receptor (EGFR). Currently, erlotinib, at a standard oral daily dose of 150 mg, is …

Non-small-cell lung cancer (NSCLC) is the leading cause of cancer-related deaths. In the
last decade the EGF receptor (EGFR) signaling pathway has emerged as one of the most …

Erlotinib is an orally administered small molecule inhibitor of epidermal growth factor
receptor (EGFR) tyrosine kinase. Erlotinib at the standard oral daily dose of 150 mg is …

Inhibition of epidermal growth factor receptor (EGFR) has become an important target in the
treatment of advanced non-small cell lung cancer (NSCLC). Erlotinib and gefitinib, two small …

Erlotinib (Tarceva™, OSI-774; Pfizer, Inc.) is an orally-active, targeted inhibitor of the
epidermal growth factor receptor (EGFR/HER1), which is part of a key regulatory pathway in …

Approximately 213,380 new cases of non-small-cell lung cancer (NSCLC) were estimated to
occur in the USA in 2007, which caused 160,390 NSCLC-related deaths. The majority of …

The epidermal growth factor receptor (EGFR) is a transmembrane tyrosine kinase (TK)
receptor that is frequently expressed in many epithelial tumors. The signaling pathways of …

Learning Objectives After completing this course, the reader will be able to: Describe the
molecular mechanism of action of erlotinib. Define clinical and molecular predictors of …

Non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related deaths. In
the last decade, the epidermal growth factor receptor (EGFR) signalling pathway has …